Irini Schenkel

Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment

Bernd Löwe, Irini Schenkel, Caroline Carney-Doebbeling et al. · Psychosomatics · 2005 · 133 citations

Psychopharmacological Depression Treatment, Psychiatry, Medicine +9

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

Katrin Hoffmann, Hanno Glimm, Boris Radeleff et al. · BMC Cancer · 2008 · 96 citations · Full text

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study

Elke Pfaff, Gnana Prakash Balasubramanian, Anne Berberich et al. · Neuro-Oncology · 2017 · 38 citations · Full text

Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: Prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients

Bernd Löwe, Irini Schenkel, Matthew J. Bair et al. · Journal of Affective Disorders · 2005 · 34 citations

Non-pharmacological Intervention, Clinical Effectiveness, Psychiatry +7

A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).

Michael Platten, Daniela Schilling, Theresa Bunse et al. · Journal of Clinical Oncology · 2016 · 34 citations